P. Le

发表

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.

M. Pairish, R. Kania, S. Bagrodia, 2013, Bioorganic & medicinal chemistry letters.

The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.

A. Fanjul, P. Rejto, G. Paderes, 2010, Bioorganic & medicinal chemistry letters.

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

Wei Liu, Huichun Zhu, Dac Dinh, 2014, Journal of medicinal chemistry.

Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.

D. Knighton, S. Bagrodia, A. Pannifer, 2012, Bioorganic & Medicinal Chemistry Letters.

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

Huichun Zhu, Benjamin J. Burke, John Charles Kath, 2014 .

The discovery and structure-activity relationships leading to CE-156811, a difluorophenyl cyclopropyl fluoroether: a novel potent antibacterial analog derived from hygromycin A.

S. J. Brickner, J. Liras, G. Stone, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of novel hygromycin A antibacterial agents.

S. J. Brickner, Dianna E. Moore, K. Brighty, 2010, Bioorganic & medicinal chemistry letters.

In Vitro Antibacterial Activity of CE-156811, a Novel Analog Derived from Hygromycin A

M. Huband, S. J. Brickner, G. Stone, 2008, Antimicrobial Agents and Chemotherapy.

Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of

J. Christensen, J. Cui, M. Tran-Dube, 2012, Journal of medicinal chemistry.

Two acridones and two coumarins from the roots of Paramignya trimera

N. Nguyen, P. Dang, M. T. T. Nguyen, 2017 .

Development of a Scalable Synthesis of 4-Aminopyrimidin-5-ol, a Versatile Intermediate

N. Sach, P. Richardson, L. Xue, 2015 .

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

N. Sach, Hong Shen, M. McTigue, 2014, Journal of medicinal chemistry.

Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1.

N. Sach, M. McTigue, Sergei L Timofeevski, 2023, Journal of medicinal chemistry.

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

N. Sach, M. McTigue, H. Zou, 2013 .

Effect of water solvation on the lipophilicity of isomeric pyrimidine-carboxamides.

K. Gajiwala, B. Burke, S. Ninkovic, 2015, Bioorganic & medicinal chemistry.

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

N. Sach, H. Zou, R. Kania, 2014 .